表紙
市場調査レポート

腎臓癌治療薬の世界市場 (2015-2019年)

Global Kidney Cancer Drugs Market 2015-2019

発行 TechNavio (Infiniti Research Ltd.) 商品コード 264450
出版日 ページ情報 英文 105 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
腎臓癌治療薬の世界市場 (2015-2019年) Global Kidney Cancer Drugs Market 2015-2019
出版日: 2015年07月01日 ページ情報: 英文 105 Pages
概要

腎臓癌は腎臓の細胞に悪影響をもたらす疾患です。RCC (腎細胞癌) は成人において最も一般的な腎臓癌の種類であり、子供の場合にはウィルムス腫瘍が主要なものとなります。この病気の原因は明確に解明されていません。腎臓癌の症状は、他の腎臓疾患と混同される場合が多々あり、このことが疾患の発見の遅れを招いて患者の生存率の低下につながっています。多くの場合、患者が他の疾患の検査を行った際に判明するなど、概して偶然に発見される傾向にあります。腎臓から癌に侵された細胞を外科手術で除去することによって、この疾患を完全に治療することができます。また、数種類の薬剤が存在し、早期発見時の治療に使えるものもあります。TechNavioのアナリストは、世界の腎臓癌治療薬市場が2014年から2019年にかけてCAGR (複合年間成長率) 7.36%で成長すると予測しています。

当レポートでは、世界の腎臓癌治療薬市場を取り上げ、市場の概要、市場発展促進要因、市場における課題、ならびにそれらの影響を概括し、パイプライン分析を行うとともに、分子タイプ別・地域別に市場の現状と見通しについて調査分析し、主なベンダーのプロファイルをまとめています。

第1章 エグゼクティブサマリー

第2章 略語集

第3章 調査範囲

  • 市場概要
  • 提供製品

第4章 市場調査手法

  • 市場調査の過程
  • 調査手法

第5章 製品のプロファイル

  • Nexavar
  • Avastin
  • Votrient
  • Afinitor/Votubia
  • Proleukin
  • Inlyta
  • Sutent
  • Torisel

第6章 イントロダクション

第7章 疾患の概要

  • 疾患を理解する
    • 腎臓癌の種類
    • 良性腎腫瘍
  • リスク要素
    • ライフスタイルおよび職業に関連したリスク要素
    • 遺伝的、先天的リスク要素
    • その他のリスク要素
  • 病因と発症
    • 先天的遺伝子変異
    • 後天的遺伝子変異
  • 兆候と症状
  • 診断
    • 病歴と健康診断
    • 研究所の検査
    • 画像検査
    • 生体検査
  • 病期
    • TNM分類システム
  • 管理
    • 手術
    • 除去およびその他の局所治療
    • 放射線治療 (RT)
    • 標的 (ターゲット) 療法
    • 生物学的療法 (免疫療法)
    • 化学療法
  • 疫学
  • 経済的負担

第8章 パイプライン分析

  • パイプライン候補に関する主な情報
    • AGS-003
    • Rencarex
    • Cometriq
    • IMA901
    • AV-951
    • TroVax
    • MPDL3280A
    • Opdivo
    • Naptumomab Estafenatox
    • Carfilzomib

第9章 市場情勢

  • 市場概要
  • 市場規模と予測
  • ファイブフォース分析

第10章 市場区分、分子タイプ別

  • 小分子
  • 生物薬剤

第11章 地域別区分

第12章 購入条件

第13章 市場成長促進要因

第14章 促進要因とその影響

第15章 市場における課題

第16章 促進要因と課題の影響

第17章 市場動向

第18章 動向とその影響

第19章 ベンダー情勢

  • 競合シナリオ
    • 主なニュース
    • 吸収・合併
  • 市場シェア分析、2014年
    • Bayer
    • Hoffmann-La Roche
    • GlaxoSmithKline
    • Novartis
    • Pfizer
  • その他および将来において注目すべきベンダー

第20章 世界の腎臓癌治療薬市場:主な調査結果

第21章 主なベンダーの分析 (主な情報、事業概要、事業区分別売上、地域別売上、事業戦略、最近の動向、SWOT分析)

  • Bayer
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Novartis
  • Pfizer

第22章 本シリーズにおける他のレポート

図表リスト

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: IRTNTR6298

About Kidney Cancer

Kidney cancer also known as renal cancer affects the kidney cells. RCC is the most common form of kidney cancer in adults and Wilms' tumor in children. The exact cause of the disease is not yet known. The symptoms of renal cancer are often confused with other kidney disorders. This usually results in late stage detection of the disease, which leads to less chances of patient survival. In the majority of cases, it is diagnosed accidentally, when the patient undergoes checkups for other disorders.

Kidney cancer can be triggered by a number of factors including both lifestyle-related changes and genetic changes. The surgical removal of affected cancerous cells from the kidney provides a complete cure of the disease. A number of drugs are also available, which also help in the treatment of the disease when it is diagnosed at earlier stages.

Technavio's analysts forecast the global kidney cancer drugs market to grow at a CAGR of 7.36% over the period 2014-2019.

Covered in this Report

The report covers the present scenario and the growth prospects of the global kidney cancer drugs market for 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various approved therapies and off-label drugs used for the treatment of kidney cancer.

The three regions covered in the report are as follows:

  • Americas: US, Canada, Mexico, and Brazil
  • EMEA: UK, Germany, Italy, France, and Spain and Middle Eastern and African countries such Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and UAE
  • APAC: Japan, China, Australia, Singapore, South Korea, and India.

Technavio's report, Global Kidney Cancer Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Bayer
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • Novartis
  • Pfizer

Other Prominent Vendors

  • Abbott Laboratories
  • Active Biotech
  • Amgen
  • Argos Therapeutics
  • ArQule
  • AVEO Pharmaceuticals
  • Bionomics
  • Bristol-Myers Squibb
  • Cerulean Pharma
  • Exelixis
  • Genentech
  • immatics biotechnologies
  • Immunicum
  • Ono Pharmaceutical
  • Onyx Therapeutics
  • Oxford BioMedica
  • Prometheus Laboratories
  • Seattle Genetics
  • Taiwan Liposome
  • TRACON Pharmaceuticals
  • Wilex

Market Driver

  • Increase in Patient Population
  • For a full, detailed list, view our report

Market Challenge

  • High Cost of Drugs
  • For a full, detailed list, view our report

Market Trend

  • Strategic Alliances
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Product Profiles

    • 05.1.1. Nexavar
    • 05.1.2. Avastin
    • 05.1.3. Votrient
    • 05.1.4. Afinitor/Votubia
    • 05.1.5. Proleukin
    • 05.1.6. Inlyta
    • 05.1.7. Sutent
    • 05.1.8. Torisel

06. Introduction

07. Disease Overview

  • 07.1. Understanding the Disease
    • 07.1.1. Types of Kidney Cancer
    • 07.1.2. Benign Kidney Tumors
  • 07.2. Risk Factors
    • 07.2.1. Lifestyle and Job-related Risk Factors
    • 07.2.2. Genetic and Hereditary Risk Factors
    • 07.2.3. Other Risk Factors
  • 07.3. Etiology and Pathogenesis
    • 07.3.1. Inherited Gene Mutations
    • 07.3.2. Acquired Gene Mutations
  • 07.4. Signs and Symptoms
  • 07.5. Diagnosis
    • 07.5.1. Medical History and Physical Exam
    • 07.5.2. Lab Tests
    • 07.5.3. Imaging Tests
    • 07.5.4. Biopsy
  • 07.6. Staging
    • 07.6.1. TNM Staging System
  • 07.7. Management
    • 07.7.1. Surgery
    • 07.7.2. Ablation and Other Local Therapies
    • 07.7.3. Radiation Therapy
    • 07.7.4. Targeted Therapy
    • 07.7.5. Biologic Therapy (Immunotherapy)
    • 07.7.6. Chemotherapy
  • 07.8. Epidemiology
  • 07.9. Economic Burden

08. Pipeline Analysis

  • 08.1. Key Information on Pipeline Candidates
    • 08.1.1. AGS-003
    • 08.1.2. Rencarex
    • 08.1.3. Cometriq
    • 08.1.4. IMA901
    • 08.1.5. AV-951
    • 08.1.6. TroVax
    • 08.1.7. MPDL3280A
    • 08.1.8. Opdivo
    • 08.1.9. Naptumomab Estafenatox
    • 08.1.10. Carfilzomib

09. Market Landscape

  • 09.1. Market Overview
  • 09.2. Market Size and Forecast
  • 09.3. Five Forces Analysis

10. Market Segmentation by Molecule Type

  • 10.1. Small Molecules
  • 10.2. Biologics

11. Geographical Segmentation

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and Their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and Their Impact

19. Vendor Landscape

  • 19.1. Competitive Scenario
    • 19.1.1. Key News
    • 19.1.2. Mergers and Acquisitions
  • 19.2. Market Share Analysis 2014
    • 19.2.1. Bayer
    • 19.2.2. F. Hoffmann-La Roche
    • 19.2.3. GlaxoSmithKline
    • 19.2.4. Novartis
    • 19.2.5. Pfizer
  • 19.3. Other and Future Prominent Vendors

20. Global Kidney Cancer Drugs Market: Key Takeaways

21. Key Vendor Analysis

  • 21.1. Bayer
    • 21.1.1. Key Facts
    • 21.1.2. Business Overview
    • 21.1.3. Business Segmentation by Revenue 2014
    • 21.1.4. Business Segmentation by Revenue 2013 and 2014
    • 21.1.5. Geographical Segmentation by Revenue 2014
    • 21.1.6. Business Strategy
    • 21.1.7. Recent Developments
    • 21.1.8. SWOT Analysis
  • 21.2. F. Hoffmann-La Roche
    • 21.2.1. Key Facts
    • 21.2.2. Business Overview
    • 21.2.3. Business Segmentation
    • 21.2.4. Business Segmentation by Revenue 2012 and 2013
    • 21.2.5. Sales by Geography
    • 21.2.6. Business Strategy
    • 21.2.7. Key Information
    • 21.2.8. SWOT Analysis
  • 21.3. GlaxoSmithKline
    • 21.3.1. Key Facts
    • 21.3.2. Business Overview
    • 21.3.3. Business Segmentation by Revenue 2014
    • 21.3.4. Business Segmentation by Revenue 2013 and 2014
    • 21.3.5. Geographical Segmentation by Revenue 2014
    • 21.3.6. Business Strategy
    • 21.3.7. Recent Developments
    • 21.3.8. SWOT Analysis
  • 21.4. Novartis
    • 21.4.1. Key Facts
    • 21.4.2. Business Description
    • 21.4.3. Business Segmentation
    • 21.4.4. Revenue by Business Segmentation
    • 21.4.5. Revenue Comparison 2012 and 2013
    • 21.4.6. Sales by Geography
    • 21.4.7. Business Strategy
    • 21.4.8. Key Developments
    • 21.4.9. SWOT Analysis
  • 21.5. Pfizer
    • 21.5.1. Key Facts
    • 21.5.2. Business Overview
    • 21.5.3. Business Segmentation by Revenue 2014
    • 21.5.4. Business Segmentation by Revenue 2013 and 2014
    • 21.5.5. Geographical Segmentation by Revenue 2014
    • 21.5.6. Business Strategy
    • 21.5.7. Key Developments
    • 21.5.8. SWOT Analysis

22. Other Reports in This Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Types of Kidney Cancer
  • Exhibit 3: Types of Benign Kidney Tumor
  • Exhibit 4: Prevalence of Kidney Cancer by Gender
  • Exhibit 5: Global Kidney Cancer Drugs Market: Pipeline Portfolio
  • Exhibit 6: Global Kidney Cancer Drugs Market 2014-2019 ($ billions)
  • Exhibit 7: Segmentation of Global Kidney Cancer Drugs Market by Molecule Type
  • Exhibit 8: Segmentation of Global Kidney Cancer Drugs Market by Geography 2014
  • Exhibit 9: Major Drivers in Global Kidney Cancer Drugs Market
  • Exhibit 10: Major Challenges in Global Kidney Cancer Drugs Market
  • Exhibit 11: Major Trends of Global Kidney Cancer Drugs Market
  • Exhibit 12: Bayer: YoY Growth and Revenue of Nexavar 2010-2014 ($ millions)
  • Exhibit 13: F. Hoffmann-La Roche: YoY Growth and Revenue of Avastin 2010-2014 ($ millions)
  • Exhibit 14: GlaxoSmithKline: YoY Growth and Revenue of Votrient 2010-2014 ($ millions)
  • Exhibit 15: GlaxoSmithKline: Revenue of Votrient by Region 2010-2014 ($ millions)
  • Exhibit 16: Novartis: YoY Growth and Revenue of Afinitor 2010-2014 ($ millions)
  • Exhibit 17: Novartis: Revenue of Afinitor by Region 2012-2013 ($ millions)
  • Exhibit 18: Novartis: YoY Growth and Revenue of Proleukin 2012-2014 ($ millions)
  • Exhibit 19: Pfizer: YoY Growth and Revenue of Inlyta 2012-2014 ($ millions)
  • Exhibit 20: Pfizer: YoY Growth and Revenue of Sutent 2010-2014 ($ millions)
  • Exhibit 21: Global Kidney Cancer Drugs Market: Key Takeaways
  • Exhibit 22: Bayer: Business Segmentation by Revenue 2014
  • Exhibit 23: Bayer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
  • Exhibit 24: Bayer: Geographical Segmentation by Revenue 2014
  • Exhibit 25: Business Segmentation of F. Hoffmann-La Roche 2013
  • Exhibit 26: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013
  • Exhibit 27: F. Hoffmann-La Roche: Sales by Geography 2013 (Pharmaceuticals Division)
  • Exhibit 28: F. Hoffmann-La Roche: Sales by Geography 2013 (Diagnostics Division)
  • Exhibit 29: GlaxoSmithKline: Business Segmentation by Revenue 2014
  • Exhibit 30: GlaxoSmithKline: Business Segmentation by Revenue 2013 and 2014 ($ billions)
  • Exhibit 31: GlaxoSmithKline: Geographical Segmentation by Revenue 2014
  • Exhibit 32: Novartis: Business Segmentation
  • Exhibit 33: Novartis: Revenue by Business Segmentation 2013
  • Exhibit 34: Novartis: Revenue by Business Segmentation 2012 and 2013 ($ millions)
  • Exhibit 35: Novartis: Revenue by Geographical Segmentation 2013
  • Exhibit 36: Pfizer: Business Segmentation by Revenue 2014
  • Exhibit 37: Pfizer: Business Segmentation by Revenue 2013 and 2014 ($ billions)
  • Exhibit 38: Pfizer: Geographical Segmentation by Revenue 2014
Back to Top